The CDISC Board of Directors (BoD) provides strategic leadership, governance, and oversight to guide the organization’s mission of advancing clinical data standards worldwide.
Through their expertise and commitment, Board members work closely with leadership, stakeholders, and the global clinical research community to strengthen CDISC’s impact, uphold its mission, and ensure it remains a trusted, innovative leader in clinical data standards.
CDISC actively encourages participation in our Board of Directors. We seek individuals who are passionate about our mission and bring strong leadership, strategic vision, and a collaborative spirit to help shape the future of clinical research and data standards. Ideal candidates will have experience in areas such as data governance, regulatory affairs, finance, and fundraising.
We welcome both nominations and self-nominations. Please ensure nominees are willing and able to commit to approximately four virtual and two in-person meetings annually. Submissions should include a current CV or LinkedIn profile and a cover letter outlining the candidate’s interest and qualifications.
Jonathan Chainey
ChairJonathan Chainey is an Executive Director and Global Head, Data Standards & Governance within Data Sciences, Product Development at Roche. He leads a global team accountable for the cross-functional governance and adoption of Roche’s CDISC-aligned global data standards across all Roche sponsored early & late phase clinical trials. Prior to his election to the CDISC Board of Directors, Jonathan served as chair of the CDISC Advisory Council.
Over the past 25 years Jonathan has worked within the biopharmaceutical industry in the U.K., Switzerland, and United States in a range of disciplines including pre-clinical pharmacological research (Ciba-Geigy), clinical data management (Parexel), statistical programming & analysis (Pfizer, Novartis), applications development (Pfizer, Roche), and process analysis, data standards & governance (Roche). Jonathan has a scientific background and education including a BSc (Hons) Pharmacology, University of Bath, U.K. He is a British citizen and currently located in the San Francisco Bay Area, California.
Patti Compton
Patti oversees the curation of datasets and production of tables, listing and figures to support clinical trials, modeling/simulation, and submissions as the VP & Global Head of Statistical Data Sciences and Analytics at Pfizer. She is a proponent of cultivating the value of data through data sharing, streamed submissions, and colleague growth and connection across the industry. Patti currently serves on multiple advisory groups and is interested in accelerating the sharing of data with patients, business partners, and healthcare organizations.
She has more than 25 years of experience in the pharmaceutical academic sector. In addition to bolstering data reporting settings, quality indicators, and data sharing capabilities. Patti is currently leading efforts to develop a sustainable framework to maximize data delivery and analytics. She is responsible for operational expansion of the data sector throughout Asia, including China, India and Japan. Patti serves as a business sponsor, implementing the methods and technologies necessary to provide a solid foundation for distribution of data, including modern research methodology, digital tools (Automation/AI), real-world evidence strategies.
Patti is a board member of the Society for Women's Health Research (SWHR) and a member of Pharma Statistical Programming Heads Council.
Rhona O'Donnell
Chair-ElectRhona O’Donnell has over 20 years’ experience in the clinical trials industry. She is currently VP, Data Standards & Integration at Novo Nordisk, overseeing clinical data standards, clinical data systems and data transformation across the Novo Nordisk value chain. Previously, Rhona held the position of VP, Data Management & Clinical Risk Management at ICON, working with multiple Sponsor partners across Data Management and Clinical Risk Management over the course of 19 years. Her experience spans global data management project delivery, EDC/clinical database and data transformation strategy and management, operational delivery model design, business unit financial and commercial management, clinical risk management, technical system selection and implementation as well as extensive experience in change control and process improvement projects.
Rhona holds an B.Sc. (Hons) in Experimental Physics from University College Dublin and an M.Sc. in Management from Michael Smurfit Graduate Business School, University College Dublin and is currently serving as a Board Member and Company Secretary for ECO-UNESCO, an environmental education and youth organization based in Ireland.
Brooke Hinkson
Past-ChairBrooke Hinkson has over 30 years of clinical research experience in various settings including a clinical research organization, healthcare provider, technology vendor, and biopharmaceutical companies. She is the Executive Director, Global Clinical Data Standards at Merck & Co., Inc., Kenilworth, NJ, USA in support of enabling process optimization, technology-enabled information management, and compliance with regulation and guidance for clinical study data. For over the past two decades, Brooke has extensive experience defining clinical data standards strategies and standards operating models to support the adoption, definition, use, sharing and governance of standards. Brooke has a passion for change and a desire to treat information as a strategic asset and leverage standards to accelerate delivering therapies to patients.
Yuki Ando, PhD
Yuki Ando is a Principal Senior Scientist in Biostatistics at the Pharmaceuticals and Medical Devices Agency (PMDA). With over 25 years of experience as a Biostatistics Reviewer, she is currently responsible for biostatistics review and consultation in the new drug offices at PMDA.
Since 2013, when discussions began in Japan about requiring the submission of patient-level clinical study data in CDISC standardized format as part of new drug applications, she has been deeply involved in the project. To date, she has contributed to various aspects of this electronic data submission initiative, including the development and dissemination of regulatory guidance documents and validation rules, the review and decision-making process regarding dataset acceptance or rejection, and coordination with key stakeholders such as pharmaceutical industry associations, CROs, and academic organizations. Additionally, she has experience in the development of ICH guidelines, including E9(R1), E8(R1), and E20, as a member of the Expert Working Groups.
Yuki holds an M.Sc. in Engineering from the Tokyo University of Science and a Ph.D. in Health Science from Osaka University.
Jennifer Bittinger
Throughout the past 20 years, Jennifer has built a career as an entrepreneur, industry leader, executive, marketing innovator, and branded content specialist empowering clients to take advantage of the newest technological advancements to grow their global reach, including Entertainment Tonight, Dr. Phil, Cesar Millan, TBS, Hulu, Beliefnet, OWN, San Francisco Giants, Chevron, ExxonMobil, Pfizer, Johnson & Johnson, ICON, Wall Street Journal and more. Jennifer currently serves as the President and Co-Founder of Narrativa, one of the fastest growing artificial intelligence (AI) companies that specializes in automating regulatory documents for the Life Sciences Industry.
Scott Chetham, PhD
Scott Chetham, PhD, is a healthcare entrepreneur and clinical development leader, and serves as Chief Executive Officer and Co-Founder of Faro Health, where he focuses on improving clinical development decision-making by applying structured data, standards, and generative artificial intelligence to the design and execution of clinical studies.
Previously, Dr. Chetham was Head of Clinical Research Operations and Data Management at Verily Life Sciences (formerly Google Life Sciences), where he led clinical strategy, operations, data management, and process development across the company’s clinical portfolio, including programs originating from Google and X.
Earlier in his career, he served as a Venture Partner at Versant Ventures and held senior leadership roles at Intersection Medical (acquired by ImpediMed) and ImpediMed, including Chief Technology Officer and Vice President of Clinical Affairs, with responsibility for clinical research strategy and execution.
Dr. Chetham began his career as a clinical scientist in global medical device and biopharmaceutical development.
Catherine Chronaki, MBA
Catherine Chronaki is Secretary General at the HL7 Europe Foundation and served as the President of the European Federation for Medical Informatics (EFMI) from 2020 through 2022. A computer engineer by training, Chronaki has engaged in eHealth projects since the early 1990s. Her work has focused on designing, implementing, and evaluating health information infrastructures, employing interoperability standards, and extending electronic health records (EHRs) to support disease surveillance and emergency management. Her extensive contributions to eHealth projects have been instrumental in advancing healthcare innovation in Europe and beyond.
Karen Curran, MBA
Karen Curran is a Chief Strategic Officer at Veramed. She has 25+ years in the Biopharma Industry with Clinical Research Organizations, leading global teams across Standards & Innovation, Data Management, Statistics, Statistical Programming and Medical Writing. With a proven ability to successfully develop, manage and grow dynamic global business units, Karen also has market Expertise in providing strategic guidance and developing innovative solutions for biometric processes, including CDISC adoption and implementation, on both large and small pharma and CRO environments.
Karen has extensive CDISC management knowledge and submission experience including the FDA, EMEA and the PMDA alongside an active leadership involvement in the PHUSE organisation for 5+ years and being a member of the CDISC Board of Directors.
Prior to Veramed, Karen held roles as the Vice President, Global Strategic Partnerships at IQVIA, Vice President and General Manager at CSG, and the Vice President of Global Strategic Partnerships at Covance. Karen received her BS in Mathematics from Shippensburg University, and her MBA from Penn State University.
Ron Fitzmartin, PhD, MBA
Ron Fitzmartin, PhD, MBA, is a regulatory science and drug development leader with 25+ years of experience advancing regulatory policy, data standards, and modern submission processes across government and industry. He is known for building multidisciplinary teams and delivering complex initiatives that improve data quality, interoperability, and regulatory decision-making.
He is the Principal Consultant at Decision Analytics, LLC, where he advises regulators, global health partners, and industry on implementing global data standards, streamlining submissions, and improving end-to-end data governance. His recent work includes benchmarking and evaluating generative AI tools for regulatory use, using practical performance metrics and blinded comparisons to assess reliability, consistency, and fitness for real-world regulatory workflows.
From 2012 to 2025, Ron served at the U.S. Food and Drug Administration as a Senior Informatics Advisor in both CDER and CBER. He led key standardized study data policy initiatives, supported FDA’s work on IDMP guidance and global implementation, and held leadership roles in ICH, including regulatory chair for the ICH M8 Electronic Submissions EWG and rapporteur for the ICH M11 Clinical Protocol Template EWG.
Bill Illis
Bill has over 30 years of industry experience in R&D spanning domains of cancer epidemiology, health care cost/utilization research preclinical safety, clinical development and regulatory fffairs including functional leadership in data management, programming, statistics, data standards and governance, information technology and operations.
Bill is currently Executive Director, Technology & Statistical Computing, in the Advanced Quantitative Sciences function of Global Drug Development at Novartis, based in East Hanover, NJ. He is responsible for developing and implementing the analytics technology strategy focused on end-to-end clinical data flows, systems and processes and overseeing a portfolio of analytics capability development. For the past several years he has also served as the industry workstream lead for the Digital Data Flow initiative at the pharmaceutical industry consortium TransCelerate Biopharma working in close collaboration with CDISC developing USDM data standard and digital protocol interoperability solutions.
Prior to Novartis Bill worked at Dun & Bradstreet on the acquisition and analysis of health care cost and utilization data, and at the Michigan Cancer Foundation supporting National Institutes of Health, SEER Program and the production of population-based cancer incidence statistics and associated research. He holds a Master of Public Health degree from the University of Michigan.
Lisa Lin, MBA
Lisa Lin is a Study Data Standards Manager at FDA CBER (Center for Biologics Evaluation and Research). Currently she is responsible for all study data standards projects in CBER, including study data validation, evaluation and testing of the SEND standard for CBER, data standards and analysis tool training and support for CBER reviewers.
Before joining CBER, Lisa worked at CDER (Center of Drug Evaluation and Research) as a Data Standards Lead. She played an important role of leading CDER on study data standards development and implementation and her contribution includes the Development of Technical Rejection Criteria, Technical Conformance Guide, FDA Business Rules, FDA Data Standards Catalog, various technical specification guides, eData mailbox, training and support of analysis tools, consultation on Pre-NDA/Pre-BLA/IND meetings. Before joining FDA, Lisa contributed extensive experience and strong technical background working on CDISC data standards and clinical trial data analysis and submissions in several pharmaceutical companies. She received her MBA from West Chester University.
Patrick Nadolny
Patrick Nadolny, Global Head of Clinical Data Management at Sanofi, brings over 30 years of experience spanning pharmaceuticals, medical devices, and biologics. Nadolny is the current Board Chair of the Society for Clinical Data Management (SCDM), where he has also led the innovation committee, driving the evolution of clinical data management toward clinical data science. His expertise includes strategic planning, technology innovation, and change management.